Jupiter Asset Management Ltd. Has $5.42 Million Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Jupiter Asset Management Ltd. reduced its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 15.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,223,275 shares of the biotechnology company's stock after selling 225,160 shares during the period. Jupiter Asset Management Ltd. owned about 0.76% of Ironwood Pharmaceuticals worth $5,419,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. KBC Group NV lifted its stake in Ironwood Pharmaceuticals by 59.3% during the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 3,198 shares during the last quarter. Journey Strategic Wealth LLC acquired a new stake in Ironwood Pharmaceuticals in the 4th quarter worth approximately $45,000. Wolverine Trading LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the third quarter valued at about $51,000. SG Americas Securities LLC acquired a new position in Ironwood Pharmaceuticals during the 4th quarter valued at $53,000. Finally, CIBC Asset Management Inc bought a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter worth approximately $53,000.

Insider Activity

In other Ironwood Pharmaceuticals news, CMO Michael Shetzline sold 41,269 shares of the company's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the transaction, the chief marketing officer now directly owns 554,007 shares in the company, valued at $975,052.32. The trade was a 6.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Thomas A. Mccourt sold 139,064 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $244,752.64. Following the sale, the chief executive officer now directly owns 1,160,634 shares of the company's stock, valued at $2,042,715.84. The trade was a 10.70 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 192,381 shares of company stock valued at $338,591 in the last quarter. Company insiders own 12.90% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Craig Hallum decreased their price target on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, January 22nd. JMP Securities dropped their target price on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating on the stock in a report on Thursday, January 30th. Finally, StockNews.com raised shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $8.60.

Ironwood Pharmaceuticals Stock Up 3.4 %

Shares of NASDAQ:IRWD traded up $0.05 during midday trading on Monday, reaching $1.54. The company had a trading volume of 1,733,578 shares, compared to its average volume of 2,339,614. The business's 50 day moving average price is $2.56 and its 200 day moving average price is $3.60. Ironwood Pharmaceuticals, Inc. has a 1-year low of $1.34 and a 1-year high of $9.23. The stock has a market cap of $246.44 million, a PE ratio of -51.33 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.08). The company had revenue of $90.55 million for the quarter, compared to the consensus estimate of $93.85 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. On average, research analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.